re: Ann: SPL Commences pivotal phase 3 VivaGe... Blackjack,
There may be good reasons to be skeptical about Vivagel's near-term prospects, but I don't think a Cassandran attitude about HIV mutation is one of them.
From "Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity" 2010
The authors discuss interaction of dendrimers (including Vivagel's SPL7013) with the highly mutable HIV external glycoprotein gp120:
"Our studies demonstrate that SPL7013 and SPL7115 block HIV-1 entry indicating that they bind to HIV-1 surface proteins and/or host cell receptors required for entry...Moreover, multiple mutations in HIV-1 gp120 are required to develop resistance to dendrimers as observed for the related DNAA dendrimer SPL2923"
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0012309
Regards,
JT
- Forums
- ASX - By Stock
- SPL
- Ann: SPL Commences pivotal phase 3 VivaGel BV tre
Ann: SPL Commences pivotal phase 3 VivaGel BV tre, page-5
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.1¢ |
Change
0.001(0.56%) |
Mkt cap ! $37.31M |
Open | High | Low | Value | Volume |
9.0¢ | 9.1¢ | 9.0¢ | $37.52K | 414.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 89034 | 9.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.1¢ | 66408 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 89034 | 0.090 |
1 | 127200 | 0.087 |
3 | 61395 | 0.086 |
2 | 76000 | 0.085 |
1 | 32500 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.091 | 66408 | 2 |
0.093 | 65000 | 1 |
0.095 | 40000 | 1 |
0.097 | 50000 | 1 |
0.099 | 1285 | 1 |
Last trade - 10.55am 15/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online